<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.biomedcentral.com/feeds/latestarticles/journal?journal=bmcneurol&amp;quantity=&amp;format=rss&amp;version=">
        <title>BMC Neurology - Latest Articles</title>
        <link>http://www.biomedcentral.com/bmcneurol/</link>
        <description>The latest research articles published by BMC Neurology</description>
        <dc:date>2009-12-01T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2377/9/58" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2377/9/57" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2377/9/56" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2377/9/55" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2377/9/54" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2377/9/53" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2377/9/52" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2377/9/51" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2377/9/50" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2377/9/49" />
                            </rdf:Seq>
        </items>
        <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.biomedcentral.com/1471-2377/9/58">
        <title>The burden of stroke and transient ischemic attacks in Pakistan: a community-based prevalence study.</title>
        <description>Background:
The burden of cerebrovascular diseases in developing countries is rising sharply. The prevalence of established risk factors of stroke is exceptionally high in Pakistan. However, there are limited data on the burden of stroke and transient ischemic attacks (TIA) in South Asia. We report the first such study conducted in an urban slum of Karachi, Pakistan.
Methods:
Individuals 35 years of age or older were invited for participation in this investigation through simple random sampling. A structured face-to-face interview was conducted using a pre-tested stroke symptom questionnaire in each participant to screen for past stroke or TIA followed by neurological examination of suspected cases. Anthropometric measurements and random blood glucose levels were recorded. Data was analyzed using Stata v10.0. Multivariable logistic regression was used to determine the association of pre-specified covariates with the prevalence of stroke.
Results:
545 individuals (49.4% of them were females) participated in the study with a response rate of 76.8%. 104 individuals (19.1%) were observed to have a prior stroke while TIA was found in 53 individuals (9.7%). Overall, 119 individuals (21.8% with 66.4% women) had cerebrovascular disease (including stroke and/or TIA). Female gender, increasing age, raised random blood glucose level and use of chewable tobacco were significantly associated with the prevalence of cerebrovascular disease (p&lt;0.05).
Conclusions:
This is the first study demonstrating an alarmingly high life-time prevalence of cerebrovascular disease in Pakistan.  Individual and public health interventions in Pakistan to increase awareness about stroke, its prevention and therapy are warranted.</description>
        <link>http://www.biomedcentral.com/1471-2377/9/58</link>
                <dc:creator>Ayeesha Kamran Kamal</dc:creator>
                <dc:creator>Ahmed Itrat</dc:creator>
                <dc:creator>Muhammed Murtaza</dc:creator>
                <dc:creator>Maria Khan</dc:creator>
                <dc:creator>Asif Rasheed</dc:creator>
                <dc:creator>Amin Ali</dc:creator>
                <dc:creator>Amna Akber</dc:creator>
                <dc:creator>Zainab Akber</dc:creator>
                <dc:creator>Navaid Iqbal</dc:creator>
                <dc:creator>Sana Shoukat</dc:creator>
                <dc:creator>Farzin Majeed</dc:creator>
                <dc:creator>Danish Saleheen</dc:creator>
                <dc:source>BMC Neurology 2009, 9:58</dc:source>
        <dc:date>2009-12-01T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2377-9-58</dc:identifier>
        <prism:publicationName>BMC Neurology</prism:publicationName>
        <prism:issn>1471-2377</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>58</prism:startingPage>
        <prism:publicationDate>2009-12-01T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2377/9/57">
        <title>Comparing unilateral and bilateral upper limb training: The ULTRA-stroke program design</title>
        <description>Background:
About 80% of all stroke survivors have an upper limb paresis immediately after stroke, only about a third of whom (30 to 40%) regain some dexterity within six months following conventional treatment programs. Of late, however, two recently developed interventions - constraint-induced movement therapy (CIMT) and bilateral arm training with rhythmic auditory cueing (BATRAC) - have shown promising results in the treatment of upper limb paresis in chronic stroke patients. The ULTRA-stroke (acronym for Upper Limb TRaining After stroke) program was conceived to assess the effectiveness of these interventions in subacute stroke patients and to examine how the observed changes in sensori-motor functioning relate to changes in stroke recovery mechanisms associated with peripheral stiffness, interlimb interactions, and cortical inter- and intrahemispheric networks. The present paper describes the design of this single-blinded randomized clinical trial (RCT), which has recently started and will take several years to complete.Methods/DesignSixty patients with a first ever stroke will be recruited. Patients will be stratified in terms of their remaining motor ability at the distal part of the arm (i.e., wrist and finger movements) and randomized over three intervention groups receiving modified CIMT, modified BATRAC, or an equally intensive (i.e., dose-matched) conventional treatment program for 6 weeks. Primary outcome variable is the score on the Action Research Arm test (ARAT), which will be assessed before, directly after, and 6 weeks after the intervention. During those test sessions all patients will also undergo measurements aimed at investigating the associated recovery mechanisms using haptic robots and magneto-encephalography (MEG).DiscussionULTRA-stroke is a 3-year translational research program which aims (1) to assess the relative effectiveness of the three interventions, on a group level but also as a function of patient characteristics, and (2) to delineate the functional and neurophysiological changes that are induced by those interventions.The outcome on the ARAT together with information about changes in the associated mechanisms will provide a better understanding of how specific therapies influence neurobiological changes, and which post-stroke conditions lend themselves to specific treatments.Trial RegistrationThe ULTRA-stroke program is registered at the Netherlands Trial Register (NTR, http://www.trialregister.nl, number NTR1665).</description>
        <link>http://www.biomedcentral.com/1471-2377/9/57</link>
                <dc:creator>A. (Lex) van Delden</dc:creator>
                <dc:creator>C. (Lieke) Peper</dc:creator>
                <dc:creator>Jaap Harlaar</dc:creator>
                <dc:creator>Andreas Daffertshofer</dc:creator>
                <dc:creator>Nienke Zijp</dc:creator>
                <dc:creator>Kirsten Nienhuys</dc:creator>
                <dc:creator>Peter Koppe</dc:creator>
                <dc:creator>Gert Kwakkel</dc:creator>
                <dc:creator>Peter Beek</dc:creator>
                <dc:source>BMC Neurology 2009, 9:57</dc:source>
        <dc:date>2009-11-06T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2377-9-57</dc:identifier>
        <prism:publicationName>BMC Neurology</prism:publicationName>
        <prism:issn>1471-2377</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>57</prism:startingPage>
        <prism:publicationDate>2009-11-06T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2377/9/56">
        <title>Patient with neuromyelitis optica and inflammatory demyelinating lesions comprising whole spinal cord from C2 level till conus: case report</title>
        <description>Background:
Neuromyelitis optica (NMO) is an idiopathic, severe, inflammatory demyelinating disease of the central nervous system, that causes severe optic neuritis and myelitis attacks. Early discrimination between multiple sclerosis (MS) and NMO is important, as optimum treatment for both diseases may differ considerably.Case PresentationWe report a case of a patient who initially presented as longitudinally extensive transverse myelitis (LETM), having spastic upper extremities diparesis and spastic paraplegia, C2/C3 sensory level and urinary incontinence, as well as extensive inflammatory spinal cord lesions from C2 level to conus. After 5 months the patient had another attack of transverse myelitis, had electrophysiological findings consistent with optic neuritis, was seropositive for NMO-IgG (aquaporin-4 IgG) and thus fulfilled NMO diagnostic criteria. Following treatment of disease attacks with pulse corticosteroid therapy and intravenous immunoglobulins, we included oral azathioprine in a combination with oral prednisone in the therapy. Since there was no significant clinical improvement, we decided to use cyclophosphamide therapy, which resulted in good clinical improvement and gradual decrease of cord swelling.
Conclusion:
In this NMO case report we wanted to emphasize the extensiveness of inflammatory spinal cord changes in our patient, from C2 level to conus. In the conclusion it is important to say that accurate, early diagnosis and distinction from MS is critical to facilitate initiation of immunosuppressive therapy for attack prevention.</description>
        <link>http://www.biomedcentral.com/1471-2377/9/56</link>
                <dc:creator>Zeljka Petelin Gadze</dc:creator>
                <dc:creator>Sanja Hajnsek</dc:creator>
                <dc:creator>Silvio Basic</dc:creator>
                <dc:creator>Davor Sporis</dc:creator>
                <dc:creator>Goran Pavlisa</dc:creator>
                <dc:creator>Sibila Nankovic</dc:creator>
                <dc:source>BMC Neurology 2009, 9:56</dc:source>
        <dc:date>2009-10-23T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2377-9-56</dc:identifier>
        <prism:publicationName>BMC Neurology</prism:publicationName>
        <prism:issn>1471-2377</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>56</prism:startingPage>
        <prism:publicationDate>2009-10-23T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2377/9/55">
        <title>Prevalence of dementia and major dementia
subtypes in Spanish populations: A reanalysis of dementia prevalence surveys, 1990-2008.
</title>
        <description>Background:
This study describes the prevalence of dementia and major dementia subtypes in Spanish elderly.
Methods:
We identified screening surveys, both published and unpublished, in Spanish populations, which fulfilled specific quality criteria and targeted prevalence of dementia in populations aged 70 years and above. Surveys covering 13 geographically different populations were selected (prevalence period: 1990-2008). Authors of original surveys provided methodological details of their studies through a systematic questionnaire and also raw age-specific data. Prevalence data were compared using direct adjustment and logistic regression.
Results:
The reanalyzed study population (aged 70 year and above) was composed of Central and North-Eastern Spanish sub-populations obtained from 9 surveys and totaled 12,232 persons and 1,194 cases of dementia (707 of Alzheimer&apos;s disease, 238 of vascular dementia). Results showed high variation in age- and sex-specific prevalence across studies. The reanalyzed prevalence of dementia was significantly higher in women; increased with age, particularly for Alzheimer&apos;s disease; and displayed a significant geographical variation among men. Prevalence was lowest in surveys reporting participation below 85%, studies referred to urban-mixed populations and populations diagnosed by psychiatrists.
Conclusion:
Prevalence of dementia and Alzheimer&apos;s disease in Central and North-Eastern Spain is higher in females, increases with age, and displays considerable geographic variation that may be method-related. People suffering from dementia and Alzheimer&apos;s disease in Spain may approach 600,000 and 400,000 respectively. However, existing studies may not be completely appropriate to infer prevalence of dementia and its subtypes in Spain until surveys in Southern Spain are conducted.</description>
        <link>http://www.biomedcentral.com/1471-2377/9/55</link>
                <dc:creator>Jesus de Pedro-Cuesta</dc:creator>
                <dc:creator>Javier Virues-Ortega</dc:creator>
                <dc:creator>Saturio Vega</dc:creator>
                <dc:creator>Manuel Seijo-Martinez</dc:creator>
                <dc:creator>Pedro Saz</dc:creator>
                <dc:creator>Fernanda Rodriguez</dc:creator>
                <dc:creator>Angel Rodriguez-Laso</dc:creator>
                <dc:creator>Ramon Rene</dc:creator>
                <dc:creator>Susana Perez de las Heras</dc:creator>
                <dc:creator>Raimundo Mateos</dc:creator>
                <dc:creator>Pablo Martinez-Martin</dc:creator>
                <dc:creator>Jose Maria Manubens</dc:creator>
                <dc:creator>Ignacio Mahillo-Fernandez</dc:creator>
                <dc:creator>Secundino Lopez-Pousa</dc:creator>
                <dc:creator>Antonio Lobo</dc:creator>
                <dc:creator>Jordi Llinas-Regla</dc:creator>
                <dc:creator>Jordi Gascon</dc:creator>
                <dc:creator>Francisco Jose Garcia</dc:creator>
                <dc:creator>Manuel Fernandez-Martinez</dc:creator>
                <dc:creator>Raquel Boix</dc:creator>
                <dc:creator>Felix Bermejo-Pareja</dc:creator>
                <dc:creator>Alberto Bergareche</dc:creator>
                <dc:creator>Julian Benito</dc:creator>
                <dc:creator>Ana de Arce</dc:creator>
                <dc:creator>Jose Luis del Barrio</dc:creator>
                <dc:source>BMC Neurology 2009, 9:55</dc:source>
        <dc:date>2009-10-19T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2377-9-55</dc:identifier>
        <prism:publicationName>BMC Neurology</prism:publicationName>
        <prism:issn>1471-2377</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>55</prism:startingPage>
        <prism:publicationDate>2009-10-19T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2377/9/54">
        <title>Neutralizing antibodies explain the poor clinical response to Interferon beta in a small proportion of patients with Multiple Sclerosis: a retrospective study</title>
        <description>Background:
Neutralizing antibodies (NAbs) against Interferon beta (IFN&#946;) are reported to be associated with poor clinical response to therapy in multiple sclerosis (MS) patients. We aimed to quantify the contribution of NAbs to the sub-optimal response of IFN&#946; treatment.
Methods:
We studied the prevalence of NAbs in MS patients grouped according to their clinical response to IFN&#946; during the treatment period. Patients were classified as: group A, developing &#8805; 1 relapse after the first 6 months of therapy; group B, exhibiting confirmed disability progression after the first 6 months of therapy, with or without superimposed relapses; group C, presenting a stable disease course during therapy. A cytopathic effect assay tested the presence of NAbs in a cohort of ambulatory MS patients treated with one of the available IFN&#946; formulations for at least one year. NAbs positivity was defined as NAbs titre &#8805; 20 TRU.
Results:
Seventeen patients (12.1%) were NAbs positive. NAbs positivity correlated with poorer clinical response (p &lt; 0.04). As expected, the prevalence of NAbs was significantly lower in Group C (2.1%) than in Group A (17.0%) and Group B (17.0%). However, in the groups of patients with a poor clinical response (A, B), NAbs positivity was found only in a small proportion of patients.
Conclusion:
The majority of patients with poor clinical response are NAbs negative suggesting that NAbs explains only partially the sub-optimal response to IFN&#946;.</description>
        <link>http://www.biomedcentral.com/1471-2377/9/54</link>
                <dc:creator>Emilia Sbardella</dc:creator>
                <dc:creator>Valentina Tomassini</dc:creator>
                <dc:creator>Claudio Gasperini</dc:creator>
                <dc:creator>Francesca Bellomi</dc:creator>
                <dc:creator>Luca Ausili Cefaro</dc:creator>
                <dc:creator>Vincenzo Brescia Morra</dc:creator>
                <dc:creator>Guido Antonelli</dc:creator>
                <dc:creator>Carlo Pozzilli</dc:creator>
                <dc:source>BMC Neurology 2009, 9:54</dc:source>
        <dc:date>2009-10-13T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2377-9-54</dc:identifier>
        <prism:publicationName>BMC Neurology</prism:publicationName>
        <prism:issn>1471-2377</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>54</prism:startingPage>
        <prism:publicationDate>2009-10-13T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2377/9/53">
        <title>Systematic review of pharmacological treatments in fragile X syndrome</title>
        <description>Background:
Fragile X syndrome (FXS) is considered the most common cause of inherited mental retardation. Affected people have mental impairment that can include Attention Deficit and/or Hyperactivity Disorder (ADHD), autism disorder, and speech and behavioural disorders. Several pharmacological interventions have been proposed to treat those impairments.
Methods:
Systematic review of the literature and summary of the evidence from clinical controlled trials that compared at least one pharmacological treatment with placebo or other treatment in individuals with diagnosis of FXS syndrome and assessed the efficacy and/or safety of the treatments. Studies were identified by a search of PubMed, EMBASE and the Cochrane Databases using the terms fragile X and treatment. Risk of bias of the studies was assessed by using the Cochrane Collaboration criteria.
Results:
The search identified 276 potential articles and 14 studies satisfied inclusion criteria. Of these, 10 studies on folic acid (9 with crossover design, only 1 of them with good methodological quality and low risk of bias) did not find in general significant improvements. A small sample size trial assessed dextroamphetamine and methylphenidate in patients with an additional diagnosis of ADHD and found some improvements in those taking methylphenidate, but the length of follow-up was too short. Two studies on L-acetylcarnitine, showed positive effects and no side effects in patients with an additional diagnosis of ADHD. Finally, one study on patients with an additional diagnosis of autism assessed ampakine compound CX516 and found no significant differences between treatment and placebo. Regarding safety, none of the studies that assessed that area found relevant side effects, but the number of patients included was too small to detect side effects with low incidence.
Conclusion:
Currently there is no robust evidence to support recommendations on pharmacological treatments in patients with FXS in general or in those with an additional diagnosis of ADHD or autism.</description>
        <link>http://www.biomedcentral.com/1471-2377/9/53</link>
                <dc:creator>Jose-Ramon Rueda</dc:creator>
                <dc:creator>Javier Ballesteros</dc:creator>
                <dc:creator>Maria-Isabel Tejada</dc:creator>
                <dc:source>BMC Neurology 2009, 9:53</dc:source>
        <dc:date>2009-10-13T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2377-9-53</dc:identifier>
        <prism:publicationName>BMC Neurology</prism:publicationName>
        <prism:issn>1471-2377</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>53</prism:startingPage>
        <prism:publicationDate>2009-10-13T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2377/9/52">
        <title>The impact of extended electrodiagnostic studies in Ulnar Neuropathy at the elbow</title>
        <description>Background:
This study aimed to explore the value of extended motor nerve conduction studies in patients with ulnar nerve entrapment at the elbow (UNE) in order to find the most sensitive and least time-consuming method. We wanted to evaluate the utility of examining both the sensory branch from the fifth finger and the dorsal branch of the ulnar nerve. Further we intended to study the clinical symptoms and findings, and a possible correlation between the neurophysiological findings and pain.
Methods:
The study was prospective, and 127 UNE patients who were selected consecutively from the list of patients, had a clinical and electrodiagnostic examination. Data from the most symptomatic arm were analysed and compared to the department&apos;s reference limits. Student&apos;s t - test, chi-square tests and multiple regression models were used. Two-side p-values &lt; 0.05 were considered as significant.
Results:
Ulnar paresthesias (96%) were more common than pain (60%). Reduced ulnar sensitivity (86%) and muscle strength (48%) were the most common clinical findings. Adding a third stimulation site in the elbow mid-sulcus for motor conduction velocity (MCV) to abductor digiti minimi (ADM) increased the electrodiagnostic sensitivity from 80% to 96%. Additional recording of ulnar MCV to the first dorsal interosseus muscle (FDI) increased the sensitivity from 96% to 98%. The ulnar fifth finger and dorsal branch sensory studies were abnormal in 39% and 30% of patients, respectively. Abnormal electromyography in FDI was found in 49% of the patients. Patients with and without pain had generally similar conduction velocity parameter means.
Conclusion:
We recommend three stimulation sites at the elbow for MCV to ADM. Recording from FDI is not routinely indicated. Sensory studies and electromyography do not contribute much to the sensitivity of the electrodiagnostic evaluation, but they are useful to document axonal degeneration. Most conduction parameters are unrelated to the presence of pain.</description>
        <link>http://www.biomedcentral.com/1471-2377/9/52</link>
                <dc:creator>Kari Todnem</dc:creator>
                <dc:creator>Ralf Peter Michler</dc:creator>
                <dc:creator>Tony Eugen Wader</dc:creator>
                <dc:creator>Morten Engstrom</dc:creator>
                <dc:creator>Trond Sand</dc:creator>
                <dc:source>BMC Neurology 2009, 9:52</dc:source>
        <dc:date>2009-10-09T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2377-9-52</dc:identifier>
        <prism:publicationName>BMC Neurology</prism:publicationName>
        <prism:issn>1471-2377</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>52</prism:startingPage>
        <prism:publicationDate>2009-10-09T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2377/9/51">
        <title>Oxidative stress and S-100B protein in children with bacterial meningitis</title>
        <description>Background:
Bacterial meningitis is often associated with cerebral compromise which may be responsible for neurological sequelae in nearly half of the survivors. Little is known about the mechanisms of CNS involvement in bacterial meningitis. Several studies have provided substantial evidence for the key role of nitric oxide (NO) and reactive oxygen species in the complex pathophysiology of bacterial meningitis.
Methods:
In the present study, serum and CSF levels of NO, lipid peroxide (LPO) (mediators for oxidative stress and lipid peroxidation); total thiol, superoxide dismutase (SOD) (antioxidant mediators) and S-100B protein (mediator of astrocytes activation and injury), were investigated in children with bacterial meningitis (n = 40). Albumin ratio (CSF/serum) is a marker of blood-CSF barriers integrity, while mediator index (mediator ratio/albumin ratio) is indicative of intrathecal synthesis.
Results:
Compared to normal children (n = 20), patients had lower serum albumin but higher NO, LPO, total thiol, SOD and S-100B. The ratios and indices of NO and LPO indicate blood-CSF barriers dysfunction, while the ratio of S-100B indicates intrathecal synthesis. Changes were marked among patients with positive culture and those with neurological complications. Positive correlation was found between NO index with CSF WBCs (r = 0.319, p &lt; 0.05); CSF-LPO with CSF-protein (r = 0.423, p &lt; 0.01); total thiol with LPO indices (r = 0.725, p &lt; 0.0001); S-100B and Pediatric Glasow Coma Scores (0.608, p &lt; 0.0001); CSF-LPO with CSF-S-100B (r = 0.482, p &lt; 0.002); serum-total thiol with serum S-100B (r = 0.423, p &lt; 0.01).
Conclusion:
This study suggests that loss of integrity of brain-CSF barriers, oxidative stress and S-100B may contribute to the severity and neurological complications of bacterial meningitis.</description>
        <link>http://www.biomedcentral.com/1471-2377/9/51</link>
                <dc:creator>Sherifa Hamed</dc:creator>
                <dc:creator>Enas Hamed</dc:creator>
                <dc:creator>Madeha Zakhary</dc:creator>
                <dc:source>BMC Neurology 2009, 9:51</dc:source>
        <dc:date>2009-10-08T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2377-9-51</dc:identifier>
        <prism:publicationName>BMC Neurology</prism:publicationName>
        <prism:issn>1471-2377</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>51</prism:startingPage>
        <prism:publicationDate>2009-10-08T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2377/9/50">
        <title>Upper limbs dysmetria caused by cervical spinal cord injury: a case report</title>
        <description>Background:
Upper limbs dysmetria caused by spinal cord injury is very rare. We will discuss the associated mechanism in our articles.Case presentationA 51-year-old male had sudden onset of weakness, dysmetria over bilateral upper limbs and ataxia after he fell accidentally. Brain magnetic resonance imaging (MRI) revealed no specific findings. C-spine MRI revealed C1 myelopathy and C4-6 spinal cord compression by bulged disc. The symptoms subsided after surgical intervention.
Conclusion:
Sudden onset of upper limbs dysmetria is a sign of dysfunction in cerebellum and its associated pathway. However, lesion in spinal cord can also cause cerebellar signs such as dysmetria.</description>
        <link>http://www.biomedcentral.com/1471-2377/9/50</link>
                <dc:creator>Hsun-Chang Lin</dc:creator>
                <dc:creator>Chun-Hung Chen</dc:creator>
                <dc:creator>Gim-Thean Khor</dc:creator>
                <dc:creator>Poyin Huang</dc:creator>
                <dc:source>BMC Neurology 2009, 9:50</dc:source>
        <dc:date>2009-09-24T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2377-9-50</dc:identifier>
        <prism:publicationName>BMC Neurology</prism:publicationName>
        <prism:issn>1471-2377</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>50</prism:startingPage>
        <prism:publicationDate>2009-09-24T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2377/9/49">
        <title>Determinants of participation restriction among community dwelling stroke survivors: A path analysis</title>
        <description>Background:
Apart from promoting physical recovery and assisting in activities of daily living, a major challenge in stroke rehabilitation is to minimize psychosocial morbidity and to promote the reintegration of stroke survivors into their family and community. The identification of key factors influencing long-term outcome are essential in developing more effective rehabilitation measures for reducing stroke-related morbidity. The aim of this study was to test a theoretical model of predictors of participation restriction which included the direct and indirect effects between psychosocial outcomes, physical outcome, and socio-demographic variables at 12 months after stroke.
Methods:
Data were collected from 188 stroke survivors at 12 months following their discharge from one of the two rehabilitation hospitals in Hong Kong. The settings included patients&apos; homes and residential care facilities. Path analysis was used to test a hypothesized model of participation restriction at 12 months.
Results:
The path coefficients show functional ability having the largest direct effect on participation restriction (&#946; = 0.51). The results also show that more depressive symptoms (&#946; = -0.27), low state self-esteem (&#946; = 0.20), female gender (&#946; = 0.13), older age (&#946; = -0.11) and living in a residential care facility (&#946; = -0.12) have a direct effect on participation restriction. The explanatory variables accounted for 71% of the variance in explaining participation restriction at 12 months.
Conclusion:
Identification of stroke survivors at risk of high levels of participation restriction, depressive symptoms and low self-esteem will assist health professionals to devise appropriate rehabilitation interventions that target improving both physical and psychosocial functioning.</description>
        <link>http://www.biomedcentral.com/1471-2377/9/49</link>
                <dc:creator>Janita Chau</dc:creator>
                <dc:creator>David Thompson</dc:creator>
                <dc:creator>Sheila Twinn</dc:creator>
                <dc:creator>Anne Chang</dc:creator>
                <dc:creator>Jean Woo</dc:creator>
                <dc:source>BMC Neurology 2009, 9:49</dc:source>
        <dc:date>2009-09-07T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2377-9-49</dc:identifier>
        <prism:publicationName>BMC Neurology</prism:publicationName>
        <prism:issn>1471-2377</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>49</prism:startingPage>
        <prism:publicationDate>2009-09-07T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
